Identification
Name2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
Accession NumberDB04288  (EXPT01808)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 405.5391
Monoisotopic: 405.264094027
Chemical FormulaC23H31N7
InChI KeyJTVILUUAQWQWBK-IYARVYRRSA-N
InChI
InChI=1S/C23H31N7/c24-17-10-12-18(13-11-17)27-23-28-21(25-14-16-6-2-1-3-7-16)20-22(29-23)30(15-26-20)19-8-4-5-9-19/h1-3,6-7,15,17-19H,4-5,8-14,24H2,(H2,25,27,28,29)/t17-,18-
IUPAC Name
N6-benzyl-9-cyclopentyl-N2-[(1r,4r)-4-aminocyclohexyl]-9H-purine-2,6-diamine
SMILES
[H][C@]1(N)CC[C@@]([H])(CC1)NC1=NC(NCC2=CC=CC=C2)=C2N=CN(C3CCCC3)C2=N1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Cyclin-dependent kinase 2ProteinunknownNot AvailableHumanP24941 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0337 mg/mLALOGPS
logP4.28ALOGPS
logP3.53ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)15.39ChemAxon
pKa (Strongest Basic)10.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area93.68 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity122.5 m3·mol-1ChemAxon
Polarizability47.4 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8827
Caco-2 permeable-0.603
P-glycoprotein substrateSubstrate0.6034
P-glycoprotein inhibitor INon-inhibitor0.6115
P-glycoprotein inhibitor IIInhibitor0.6708
Renal organic cation transporterInhibitor0.5817
CYP450 2C9 substrateNon-substrate0.9058
CYP450 2D6 substrateNon-substrate0.7653
CYP450 3A4 substrateNon-substrate0.6479
CYP450 1A2 substrateInhibitor0.7817
CYP450 2C9 inhibitorNon-inhibitor0.73
CYP450 2D6 inhibitorInhibitor0.8213
CYP450 2C19 inhibitorNon-inhibitor0.6141
CYP450 3A4 inhibitorInhibitor0.5601
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6198
Ames testNon AMES toxic0.7544
CarcinogenicityNon-carcinogens0.903
BiodegradationNot ready biodegradable0.9927
Rat acute toxicity2.5870 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6836
hERG inhibition (predictor II)Inhibitor0.7284
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as 6-alkylaminopurines. These are compounds that contain an alkylamine group attached at the 6-position of a purine. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassImidazopyrimidines
Direct Parent6-alkylaminopurines
Alternative ParentsBenzylamines / Secondary alkylarylamines / Cyclohexylamines / Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Monoalkylamines
Substituents6-alkylaminopurine / Benzylamine / Aminopyrimidine / Cyclohexylamine / Secondary aliphatic/aromatic amine / Monocyclic benzene moiety / N-substituted imidazole / Pyrimidine / Benzenoid / Imidolactam
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synt...
Gene Name:
CDK2
Uniprot ID:
P24941
Molecular Weight:
33929.215 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 20:54